CATEGORIES: Featured | Research

Become a Certified CMT-FOM Clinical Evaluator at the HNF Clinical Trial Readiness Summit

by | Feb 27, 2025 | 0 comments

Become a Certified CMT-FOM Clinical Evaluator at the HNF Clinical Trial Readiness Summit

The Hereditary Neuropathy Foundation (HNF) is proud to offer an exclusive opportunity to become one of the first Fully Certified CMT-FOM Clinical Evaluators at the upcoming HNF Clinical Trial Readiness Summit in Nashville, TN. This groundbreaking training will take place from April 23-26, 2025.

This is a unique and FREE training opportunity led by Dr. Joshua Burns, PhD, at St. Jude Children’s Research Hospital and Dr. Kayla Cornett, PhD, at the University of Sydney designed for clinical professionals seeking to enhance their expertise in the Charcot-Marie-Tooth disease (CMT) Functional Outcome Measure (CMT-FOM). However, participants must cover their own travel expenses to Nashville.

Why Get Fully Certified?

Upon successful completion of this program, participants will receive Full Certification, granting them:

  • Membership of the inaugural group of Certified CMT Clinical Evaluators, listed on ClinicalOutcomeMeasures.org
  • Access to ongoing training, quality assurance, and advanced online knowledge resources
  • Exclusive Q&A sessions with Master Trainers
  • Eligibility to become a Master Trainer
  • Inclusion in a global community of practice with fellow Clinical Evaluators
  • Limited Spots Available – Register ASAP!

Limited Spots Available – Register ASAP!

Space is limited, so interested candidates should register as soon as possible to secure their spot.

For more information or to register, contact us at [email protected]

Why is CMT Clinical Training More Important Than Ever?

The landscape of CMT research and clinical trials is evolving rapidly, with new therapeutic approaches emerging and more clinical trials than ever before. The ability to accurately assess functional outcomes in individuals with CMT is critical to the success of these trials. With the growing adoption of wearable technologies, digital biomarkers, and advanced clinical measures, properly trained evaluators are in high demand to ensure the reliability of trial data. By becoming fully certified, clinical professionals will be equipped with the latest skills and expertise needed to drive forward groundbreaking treatments and accelerate the pathway to a cure.

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

by | May 27, 2015 | , , | 0 Comments

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

by | Mar 9, 2015 | , , | 53 Comments

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

by | Mar 9, 2015 | , | 0 Comments

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

by | Mar 9, 2015 | , | 0 Comments

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

by | Dec 19, 2014 | , , | 12 Comments

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news